Cagrilintide (AM833)
AM833 · Long-acting amylin analog
A long-acting amylin analog being developed for appetite and weight regulation, including in combination with semaglutide.
Mechanism
Amylin and calcitonin receptor agonist
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
Adults with overweight or obesity
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Common weekly range | 1.2–4.5 mg | 1.2–4.5 mg/week | Once weekly | Same day each week | Subcutaneous | Community-reported |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Important: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
Cycle Structure
| Phase | Amount | Frequency | Weekly total |
|---|---|---|---|
| Selected planning schedule | 1.2–4.5 mg | Once weekly | 1.2–4.5 mg/week |
Peptide Vials
| Cycle | Total compound | Vials needed | How long one vial lasts |
|---|---|---|---|
| 4 weeks | 4.8–18 mg | 1–4 × 5 mg | 1.11–4.17 administrations |
| 8 weeks | 9.6–36 mg | 2–8 × 5 mg | 1.11–4.17 administrations |
| 12 weeks | 14.4–54 mg | 3–11 × 5 mg | 1.11–4.17 administrations |
Bacteriostatic Water
| Cycle | Total water used | 10 mL bottles needed |
|---|---|---|
| 4 weeks | 2–8 mL | 1 × 10 mL |
| 8 weeks | 4–16 mL | 1–2 × 10 mL |
| 12 weeks | 6–22 mL | 1–3 × 10 mL |
Insulin Syringes (U-100)
| Cycle | Administrations | Syringes needed |
|---|---|---|
| 4 weeks | 4 | 4 |
| 8 weeks | 8 | 8 |
| 12 weeks | 12 | 12 |
Ranges reflect the low and high ends of the displayed community schedule. Vials and 10 mL water bottles are rounded up; one new U-100 syringe is counted per subcutaneous administration.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Gastrointestinal events were common. Long-term benefit-risk and combination-specific effects remain under study.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.